192. Sci Rep. 2018 Jun 15;8(1):9188. doi: 10.1038/s41598-018-27315-2.The germline mutational landscape of BRCA1 and BRCA2 in Brazil.Palmero EI(1)(2), Carraro DM(3), Alemar B(4)(5), Moreira MAM(6),Ribeiro-Dos-Santos Â(7)(8), Abe-Sandes K(9), Galvão HCR(10), Reis RM(1)(11)(12), de Pádua Souza C(10), Campacci N(1), Achatz MI(13), Brianese RC(3), da CruzFormiga MN(14), Makdissi FB(15), Vargas FR(16)(17), Evangelista Dos Santos AC(6),Seuanez HN(6), Lobo de Souza KR(6), Netto CBO(18), Santos-Silva P(5), da SilvaGS(5), Burbano RMR(19), Santos S(7)(8), Assumpção PP(8), Bernardes IMM(8),Machado-Lopes TMB(9), Bomfim TF(9), Toralles MBP(9), Nascimento I(9)(20),Garicochea B(21), Simon SD(22), Noronha S(23), de Lima FT(24), Chami AM(25)(26), Bittar CM(4)(5), Bines J(27), Artigalas O(28), Esteves-Diz MDP(29), LajusTBP(30), Gifoni ACLVC(31)(32), Guindalini RSC(33), Cintra TS(34), SchwartzIVD(4)(18), Bernardi P(35), Miguel D(36), Nogueira STDS(37), Herzog J(38),Weitzel JN(38), Ashton-Prolla P(39)(40)(41).Author information: (1)Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos,Brazil.(2)Barretos School of Health Science, Faculdade de Ciências da Saúde de Barretos Dr. Paulo Prata, Barretos, Brazil.(3)International Research Center/CIPE, AC Camargo Cancer Center, Sao Paulo,Brazil.(4)Programa de Pós-Graduação em Genética e Biologia Molecular, UniversidadeFederal do Rio Grande do Sul, Porto Alegre, Brazil.(5)Laboratório de Medicina Genômica, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.(6)Programa de Genética, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.(7)Laboratório de Genética Humana e Médica, Programa de Pós-graduação em Genéticae Biologia Molecular - Universidade Federal do Pará, Belém do Pará, Brazil.(8)Núcleo de Pesquisas em Oncologia, Programa de Pós-graduação em Genética eBiologia Molecular - Universidade Federal do Pará, Belém do Pará, Brazil.(9)Laboratório de Imunologia e Biologia Molecular, Universidade Federal da Bahia,Salvador, Brazil.(10)Department of Oncogenetics, Barretos Cancer Hospital, Barretos, Brazil.(11)Life and Health Sciences Research Institute (ICVS), Health Sciences School,University of Minho, Braga, Portugal.(12)ICVS/3B's-PT Government Associate Laboratory, Braga, Guimarães, Portugal.(13)Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics -Department of Health and Human Services/Centro de Oncologia, NCI-NIH/HospitalSírio Libanês, Bethesda, USA.(14)Oncogenetics and Clinical Oncology Departments, AC Camargo Cancer Center, SãoPaulo, Brazil.(15)Breast Surgery Department, AC Camargo Cancer Center, São Paulo, Brazil.(16)Birth Defects Epidemiology Laboratory, Instituto Oswaldo Cruz, FundaçãoOswaldo Cruz, Rio de Janeiro, Brazil.(17)Genetics and Molecular Biology Department, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.(18)Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, PortoAlegre, Brazil.(19)Laboratório de Biologia Molecular, Hospital Ophir Loyola, Belem do Pará,Brazil.(20)Núcleo de Oncologia da Bahia - Grupo Oncoclínicas, Salvador, Brazil.(21)Centro de Paulista de Oncologia, Oncoclínicas, São Paulo, Brazil.(22)Departamento de Oncologia Clínica, Hospital Israelita Albert Einstein, SãoPaulo, Brazil.(23)COAEM - Centro Oncológico Antonio Ermirio de Moraes, São Paulo, Brazil.(24)Centro de Aconselhamento Genético, Hospital Israelita Albert Einstein, SãoPaulo, Brazil.(25)Rede Mater Dei de Saúde, Belo Horizonte, Brazil.(26)Instituto Hermes Pardini, Belo Horizonte, Brazil.(27)Oncopraxis, Rio de Janeiro, Brazil.(28)Hospital Moinhos de Vento (HMV), Porto Alegre, Brazil.(29)Departamento de Radiologia e Oncologia, Instituto do Câncer do Estado de São Paulo/Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.(30)Departamento de Biologia Celular e Genética - Serviço de AconselhamentoGenético, Centro de Oncologia Avançado/CECAN, Universidade Federal do Rio Grande do Norte - Hospital Liga Contra o Câncer, Natal, Brazil.(31)Rede D'Or (Fujiday and OncoStar), Fortaleza, Brazil.(32)Oncocentro, Hospital São Carlos, Fortaleza, Brazil.(33)CLION, CAM Group, Salvador, Brazil.(34)Laboratório Genoma, Vitória, Brazil.(35)Serviço de Genética Médica do Hospital Universitário, Divisão de ClínicaMédica, Universidade Federal de Santa Catarina, Florianópolis, Brazil.(36)Hospital Universitário Professor Edgard Santos, Serviço de Genética Médica,Universidade Federal da Bahia, Salvador, Brazil.(37)Departamento de Oncogenética, Oncoclin de Manaus, Manaus, Brazil.(38)Department of Population Sciences, Division of Clinical Cancer Genomics -City of Hope, Duarte, USA.(39)Programa de Pós-Graduação em Genética e Biologia Molecular, UniversidadeFederal do Rio Grande do Sul, Porto Alegre, Brazil. pprolla@gmail.com.(40)Laboratório de Medicina Genômica, Hospital de Clínicas de Porto Alegre, PortoAlegre, Brazil. pprolla@gmail.com.(41)Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, PortoAlegre, Brazil. pprolla@gmail.com.The detection of germline mutations in BRCA1 and BRCA2 is essential to theformulation of clinical management strategies, and in Brazil, there is limitedaccess to these services, mainly due to the costs/availability of genetictesting. Aiming at the identification of recurrent mutations that could beincluded in a low-cost mutation panel, used as a first screening approach, wecompiled the testing reports of 649 probands with pathogenic/likely pathogenicvariants referred to 28 public and private health care centers distributed across11 Brazilian States. Overall, 126 and 103 distinct mutations were identified inBRCA1 and BRCA2, respectively. Twenty-six novel variants were reported from both genes, and BRCA2 showed higher mutational heterogeneity. Some recurrent mutationswere reported exclusively in certain geographic regions, suggesting a foundereffect. Our findings confirm that there is significant molecular heterogeneity inthese genes among Brazilian carriers, while also suggesting that thisheterogeneity precludes the use of screening protocols that include recurrentmutation testing only. This is the first study to show that profiles of recurrentmutations may be unique to different Brazilian regions. These data should beexplored in larger regional cohorts to determine if screening with a panel ofrecurrent mutations would be effective.DOI: 10.1038/s41598-018-27315-2 PMCID: PMC6003960PMID: 29907814 